- Joined
- Jan 23, 2013
- Messages
- 30,608
UAMS Researchers Studying Using ADHD Drugs to Treat Addiction
08/28/2014
LITTLE ROCK, AR (News release) – A team of University of Arkansas for Medical Sciences (UAMS) researchers are studying the potential of two drugs used to treat Attention Deficit Hyperactivity Disorder (ADHD) in helping addicts overcome their dependence on methamphetamine.
Michael Mancino, M.D., an associate professor in the UAMS Department of Psychiatry, is the principal investigator on the first of the two-year studies, while Alison Oliveto, Ph.D., a professor in the UAMS Department of Psychiatry, is the principal investigator on the other, both funded by the National Institute on Drug Abuse.
Individuals interested in participating in the studies may call (501) 526-7969 or visit www.methresearch.com.The studies are both clinical trials using drugs approved by the Food and Drug Administration for the treatment of ADHD.
In the first trial, the only one of its kind in the United States, subjects will receive the medication lisdexamfetamine, known commercially as Vyvanse, during a one-week stay at a residential facility. The participants will then receive the drug on an outpatient basis for six weeks and continue to be followed on an outpatient basis for eight weeks after discharge from the residential facility.
In the second trial, subjects will be given the drug atomoxetine, known commercially as Strattera, for two weeks while residing at a residential facility, and then continue to receive the drug for eight weeks as outpatients.
continued http://www.arkansasmatters.com/stor...hd-drugs-to-trea/31673/GBM0kv0Z_0mDwDda4ICFNQ
.....................................................................................................................................
I have also seen people use these successfully to get and stay off coke.
08/28/2014
LITTLE ROCK, AR (News release) – A team of University of Arkansas for Medical Sciences (UAMS) researchers are studying the potential of two drugs used to treat Attention Deficit Hyperactivity Disorder (ADHD) in helping addicts overcome their dependence on methamphetamine.
Michael Mancino, M.D., an associate professor in the UAMS Department of Psychiatry, is the principal investigator on the first of the two-year studies, while Alison Oliveto, Ph.D., a professor in the UAMS Department of Psychiatry, is the principal investigator on the other, both funded by the National Institute on Drug Abuse.
Individuals interested in participating in the studies may call (501) 526-7969 or visit www.methresearch.com.The studies are both clinical trials using drugs approved by the Food and Drug Administration for the treatment of ADHD.
In the first trial, the only one of its kind in the United States, subjects will receive the medication lisdexamfetamine, known commercially as Vyvanse, during a one-week stay at a residential facility. The participants will then receive the drug on an outpatient basis for six weeks and continue to be followed on an outpatient basis for eight weeks after discharge from the residential facility.
In the second trial, subjects will be given the drug atomoxetine, known commercially as Strattera, for two weeks while residing at a residential facility, and then continue to receive the drug for eight weeks as outpatients.
continued http://www.arkansasmatters.com/stor...hd-drugs-to-trea/31673/GBM0kv0Z_0mDwDda4ICFNQ
.....................................................................................................................................
I have also seen people use these successfully to get and stay off coke.